Literature DB >> 14605249

Cystic fibrosis transmembrane conductance regulator (CFTR)-mediated residual chloride secretion does not protect against early chronic Pseudomonas aeruginosa infection in F508del homozygous cystic fibrosis patients.

Nico Derichs1, Frauke Mekus, Inez Bronsveld, Jan Bijman, Henk J Veeze, Horst von der Hardt, Burkhard Tummler, Manfred Ballmann.   

Abstract

Cystic fibrosis (CF) disease severity is characterized by a broad variability that has been attributed, in addition to the CF transmembrane conductance regulator (CFTR) genotype, to modulating factors such as CFTR-mediated residual chloride (Cl-) secretion. Moreover, CFTR has been suggested to function as a receptor for Pseudomonas aeruginosa (PA). In this study, we investigated whether or not the presence of residual Cl- secretion protects against early chronic PA colonization of patients' airways. Excluding influences on the phenotype caused by different CFTR mutations, we evaluated a cohort of F508del homozygous individuals with respect to the correlation between residual Cl- secretion and the age of onset of PA colonization as an important marker of clinical phenotype. A group with early chronic PA colonization before the age of 7 y (n = 14) was compared with a cohort that had no initial PA detection at least until the age of 13 y (n = 10). We determined the Cl- transport properties by using the intestinal current measurement in rectal suction biopsies. Residual Cl- secretion, most likely due to the CFTR Cl- channel, was observed in 63% of subjects, more frequently in early chronically PA colonized than among late or not colonized patients. These results demonstrate the presence of some active F508del-CFTR in the apical cell membrane and imply that factors other than the CFTR-mediated residual Cl- secretion determine the age of onset of PA colonization.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14605249     DOI: 10.1203/01.PDR.0000100758.66805.CE

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  6 in total

1.  DeltaF508 CFTR processing correction and activity in polarized airway and non-airway cell monolayers.

Authors:  S M Rowe; L C Pyle; A Jurkevante; K Varga; J Collawn; P A Sloane; B Woodworth; M Mazur; J Fulton; L Fan; Y Li; J Fortenberry; E J Sorscher; J P Clancy
Journal:  Pulm Pharmacol Ther       Date:  2010-03-10       Impact factor: 3.410

Review 2.  Toward inclusive therapy with CFTR modulators: Progress and challenges.

Authors:  Jennifer Guimbellot; Jyoti Sharma; Steven M Rowe
Journal:  Pediatr Pulmonol       Date:  2017-09-07

3.  Activation of the cystic fibrosis transmembrane conductance regulator by the flavonoid quercetin: potential use as a biomarker of ΔF508 cystic fibrosis transmembrane conductance regulator rescue.

Authors:  Louise C Pyle; Jennifer C Fulton; Peter A Sloane; Kyle Backer; Marina Mazur; Jeevan Prasain; Stephen Barnes; J P Clancy; Steven M Rowe
Journal:  Am J Respir Cell Mol Biol       Date:  2009-12-30       Impact factor: 6.914

4.  Eradication of Pseudomonas aeruginosa in adults with cystic fibrosis.

Authors:  S L Kenny; T D Shaw; D G Downey; J E Moore; J C Rendall; J S Elborn
Journal:  BMJ Open Respir Res       Date:  2014-04-23

5.  Personalized medicine with drugs targeting the underlying protein defect in cystic fibrosis: is monitoring of treatment response necessary?

Authors:  Katharina Niedermayr; Verena Gasser; Claudia Rueckes-Nilges; Dorothea Appelt; Johannes Eder; Teresa Fuchs; Lutz Naehrlich; Helmut Ellemunter
Journal:  Ther Adv Chronic Dis       Date:  2022-08-05       Impact factor: 4.970

6.  Genistein-induced fluid accumulation in ovariectomised rats' uteri is associated with increased cystic fibrosis transmembrane regulator expression.

Authors:  Asma Chinigarzadeh; Normadiah M Kassim; Sekaran Muniandy; Naguib Salleh
Journal:  Clinics (Sao Paulo)       Date:  2014-02       Impact factor: 2.365

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.